These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
HYMPAVZI’s safety profile was generally favorable
Captured microbes are then neutralized on engineered microbicidal surfaces
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Subscribe To Our Newsletter & Stay Updated
